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Abstract 
Background: Extracorporeal membrane oxygenation (ECMO) or pumpless extracorporeal lung assist (pECLA) 
requires effective anticoagulation. Knowledge on the use of argatroban in patients with acute respiratory distress syn‑
drome (ARDS) undergoing ECMO or pECLA is limited. Therefore, this study assessed the feasibility, efficacy and safety 
of argatroban in critically ill ARDS patients undergoing extracorporeal lung support.
Methods: This retrospective analysis included ARDS patients on extracorporeal lung support who received arga‑
troban between 2007 and 2014 in a single ARDS referral center. As controls, patients who received heparin were 
matched for age, sex, body mass index and severity of illness scores. Major and minor bleeding complications, 
thromboembolic events, administered number of erythrocyte concentrates, thrombocytes and fresh‑frozen plasmas 
were assessed. The number of extracorporeal circuit systems and extracorporeal lung support cannulas needed due 
to clotting was recorded. Also assessed was the efficacy to reach the targeted activated partial thromboplastin time 
(aPTT) in the first consecutive 14 days of therapy, and the controllability of aPTT values is within a therapeutic range of 
50–75 s. Fisher’s exact test, Mann–Whitney U tests, Friedman tests and multivariate nonparametric analyses for longi‑
tudinal data (MANOVA; Brunner’s analysis) were applied where appropriate.
Results: Of the 535 patients who met the inclusion criteria, 39 receiving argatroban and 39 matched patients receiv‑
ing heparin (controls) were included. Baseline characteristics were similar between the two groups, including severity 
of illness and organ failure scores. There were no significant differences in major and minor bleeding complications. 
Rates of thromboembolic events were generally low and were similar between the two groups, as were the rates 
of transfusions required and device‑associated complications. The controllability of both argatroban and heparin 
improved over time, with a significantly increasing probability to reach the targeted aPTT corridor over the first days 
(p < 0.001). Over time, there were significantly fewer aPTT values below the targeted aPTT goal in the argatroban 
group than in the heparin group (p < 0.05). Both argatroban and heparin reached therapeutic aPTT values for ade‑
quate application of extracorporeal lung support.
Conclusions: Argatroban appears to be a feasible, effective and safe anticoagulant for critically ill ARDS patients 
undergoing extracorporeal lung support.
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Background
The acute respiratory distress syndrome (ARDS) remains 
a major burden on intensive care units (ICU) worldwide. 
Severe cases of ARDS with life-threatening hypoxemia or 
hypercapnia can undergo extracorporeal membrane oxy-
genation (ECMO) or pumpless extracorporeal lung assist 
(pECLA) as a rescue therapy, when conservative treat-
ment strategies such as prone positioning are exhausted 
and oxygenation cannot be maintained with conven-
tional mechanical ventilation alone. However, this patient 
population might be particularly challenging with the 
simultaneous occurrence of heparin-induced throm-
bocytopenia (HIT). HIT is a serious immune-mediated 
adverse effect of heparin leading to a pro-thrombotic state 
[1–3]. Although this occurs in ≤5% of patients receiving 
heparin, its effects may be fatal, especially in critically 
ill patients [4]. Mortality rates are high, mostly resulting 
from thromboembolic events such as venous thrombo-
embolism or myocardial infarction. The clinical diagnosis 
is based on the presence of thrombocytopenia, typically 
with a platelet count drop in the first days after heparin 
administration. Suspicion of HIT must prompt discon-
tinuation of all heparin [5]. Argatroban, a direct thrombin 
inhibitor, can be used as an alternative anticoagulant to 
heparin and was shown to improve outcomes in patients 
with HIT in a prospective, historical controlled study [6].
In ARDS patients a reliable, safe and well controllable 
anticoagulation strategy is essential to ensure fault-free 
operation of the lung assist device and to keep compli-
cation rates as low as possible. Both thromboembolic 
events and bleeding are feared complications in ARDS 
patients undergoing ECMO or pECLA and contrib-
ute significantly to mortality [7]. However, knowledge 
of argatroban in critically ill patients with ARDS is lim-
ited. Considering the increasing utilization of lung assist 
devices for respiratory failure, data on alternative antico-
agulation approaches are of growing importance [8, 9].
Given the lack of prospective studies investigating arga-
troban, the present study aimed to retrospectively evalu-
ate the efficiency, safety and controllability of argatroban 
compared with standard heparin in ARDS patients 
treated with extracorporeal lung support.
Methods
Setting and patients
This retrospective, observational analysis was conducted 
at a 14-bed ICU of the department of Anesthesiology and 
Intensive Care Medicine, Charité-Universitätsmedizin 
Berlin, a national referral center for treatment of ARDS as 
part of the German ARDS network (http://www.ardsnet-
work.de). After written consent from the data protection 
officer and the hospital ethics commission (EA1/223/12), 
all adult patients (≥18 years) admitted for ARDS according 
to the Berlin definition [10] between January 2007 and 
December 2014 entered the study. Included were only 
those patients treated with extracorporeal lung assist 
devices, i.e., veno-venous extracorporeal membrane oxy-
genation (VV-ECMO) or pumpless extracorporeal lung 
assist (pECLA) for more than 2  days. Excluded were 
patients who underwent VV-ECMO/pECLA for less than 
2 days. ARDS treatment followed our local SOPs describ-
ing differential indications and duration of advanced 
therapeutic interventions following specified response cri-
teria as published previously [11]. In short, extracorporeal 
membrane oxygenation (ECMO) or pumpless extracor-
poreal lung assist (pECLA) was used as rescue therapy for 
severely hypoxemic and/or hypercapnic patients, when 
conservative treatment strategies such as prone position-
ing or inhalation of nitric oxide (NO) fail to improve the 
situation. Fast entry criteria for initiation of high-flow 
ECMO in our treatment algorithm are defined as: (1) 
paO2/FiO2 < 50 mmHg or (2) SpO2 < 90% for 2 h.
Also identified were all patients receiving argatroban 
as anticoagulant. As a control group, patients receiving 
heparin were recruited and were matched with the arga-
troban group for age, sex, body mass index (BMI) and 
the severity of illness score SAPS II. After the matching 
procedure, all the other characteristics of the patients 
given in Table 1 were compared to show that comparable 
patient groups were used.
The observation period for this study was defined as 
the total period (in days) on ECMO/pECLA and receiv-
ing either argatroban or heparin as anticoagulant.
Management of anticoagulation on extracorporeal lung 
support and measurements
All included patients received continuous argatroban or 
unfractionated heparin for anticoagulation while under-
going ECMO or pECLA. Activated partial thromboplas-
tin time (aPTT) was routinely measured three times/
day and served as a control variable for anticoagulation. 
Heparin and argatroban were titrated to an aPTT value 
of 50–75  s. Argatroban administration was considered 
upon suspicion of HIT (drop in platelet count, thrombo-
sis), or whenever patients were heparin-non-responsive. 
Then, heparin infusion was stopped and blood samples 
were obtained to perform HIT testing. According to our 
local standard, argatroban infusion was started with an 
initial dose of 0.3 µg/kg/min, which is much lower than 
the manufacturer’s recommendation.
Data collection
Clinical routine data were extracted from the two elec-
tronic patient data management systems (PDMS) in use 
at the hospital (COPRA, Sasbachwalden, Germany; and 
SAP, Walldorf, Germany).
Page 3 of 12Menk et al. Ann. Intensive Care  (2017) 7:82 
On ICU admission, in addition to basic demographic 
data (sex, age, height, weight) and anamnestic data 
(presence of comorbidities), we assessed ICU admis-
sion scores (APACHE II, SAPS II, SOFA, and TISS-28 
scores), severity of ARDS according to the Berlin defini-
tion, and calculated the lung injury score, as described 
elsewhere [12]. As major clinical causes leading to ARDS, 
a differentiation was made between pneumonia, sepsis 
of extra-pulmonary origin, trauma, immunodeficiency, 
and ‘acute on chronic’ (i.e., patients with a pre-existing 
chronic pulmonary disease with acute exacerbation). 
Also assessed was the utilization and duration of extra-
corporeal lung assist (ECMO or pECLA).
Data on the following variables were collected for 
the administration of argatroban or heparin: infusion 
start time, duration of infusion, and dose used per day. 
Table 1 Basic characteristics of ARDS patients (n = 78) on ECMO/pECLA with either argatroban or heparin
Discrete variables are presented as median and percentage and were analyzed with Fisher’s exact test for nonparametric samples. Continuous variables are presented 
as median and 25; 75 percentiles and were analyzed with Mann–Whitney U test for nonparametric samples. APACHE II Acute Physiology And Chronic Health Evaluation 
II; h hours, ICU intensive care unit; SAPS II Simplified Acute Physiology Score II. SOFA Sequential Organ Failure Assessment, TISS Therapeutic Intervention Scoring 
System. PIP positive inspiratory pressure, PEEP positive end-expiratory pressure, delta P driving pressure, FiO2 fraction of inspired oxygen, PaO2 arterial partial pressure 
of oxygen, pECLA pumpless extracorporeal lung assist, ECMO extracorporeal membrane oxygenation; complete data were available for all 78 patients 
Argatroban (n = 39) Heparin (n = 39) p value
Basic characteristics
 Age (years) 47 (36, 60) 48 (35, 64) 0.98
 Sex (male) [n] 27 (69.2%) 27 (69.2%) 0.99
 Body mass index (kg/m2) 27 (22.6, 28.7) 26 (23.2, 28.9) 0.80
Severity of illness scores at ICU admission
 SAPS II 56 (40, 71) 58 (40, 76) 0.76
 APACHE II 31 (24, 38) 28 (10.7, 38) 0.28
 SOFA 13 (9, 14) 12 (9, 15) 0.97
 TISS‑28 48 (42, 56) 50 (42, 58) 0.53
Severity of ARDS
 Mild (n) 9 (23.1%) 4 (10.3%) 0.22
 Moderate (n) 10 (25.6%) 13 (33.3%) 0.62
 Severe (n) 20 (51.3%) 22 (56.4%) 0.82
 Lung injury score (points) 3.25 (2.75, 3.5) 3.3 (2.8, 3.8) 0.51
Pulmonary gas exchange and mechanical ventilation
 PIP [cm  H2O] 36 (31, 39) 35 (32, 37) 0.58
 PEEP [cm  H2O] 18 (15, 20) 16 (14, 20) 0.18
 Delta P [cm  H2O] 19 (13, 24) 18 (15, 21) 0.84
 FiO2 1, 0 (1, 0, 1, 0) 1, 0 (0, 88, 1, 0) 0.23
 PaO2 [mmHg] 91 (70, 155) 77 (65, 117) 0.26
 PaO2/FiO2 97 (74, 166) 92 (74, 124) 0.40
 Pulmonary compliance [ml/cmH2O] 25 (15, 35) 23 (17, 36) 0.99
Etiology of ARDS
 Pneumonia (n) 18 (46.2%) 19 (48.7%) 0.95
 Sepsis (n) 1 (2.6%) 4 (10.3%) 0.36
 Immune deficiency (n) 8 (20.5%) 4 (10.3%) 0.35
 Acute on chronic (n) 7 (17.9%) 7 (17.9%) 0.99
 Trauma (n) 4 (10.3%) 0 (0%) 0.12
 Others (n) 1 (2.6%) 5 (12.8%) 0.20
Extracorporeal lung support
 pECLA (n) 9 (23.1%) 15 (38.5%) 0.20
 ECMO (n) 24 (61.5%) 19 (48.7%) 0.36
 ECMO and pECLA (n) 6 (15.4%) 5 (12.8%) 0.90
 pECLA (h) 164 (117, 258) 220 (116, 393) 0.59
 ECMO (h) 265 (131, 460) 428 (180, 652) 0.09
 ICU mortality 21 (54%) 22 (56%) 0.34
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Indications for argatroban (i.e., heparin-induced throm-
bocytopenia [HIT], heparin non-responder, etc.) were 
recorded. Clinical outcome and in-hospital mortality 
were also assessed in order to characterize the patient 
collective.
The primary safety outcome measures were docu-
mented, i.e., significant bleeding and transfusion. Sig-
nificant bleeding was subdivided into major and minor 
bleeding complications. Major bleeding was defined as 
intracranial, pulmonary, retroperitoneal, or gastrointesti-
nal bleeding found clinically or with imaging techniques. 
Minor bleeding was defined as bleeding at the site of 
puncture for central venous lines or other catheters, the 
nasopharyngeal zone, epistaxis, or from skin lesions. We 
recorded the number of units of packed red blood cells, 
fresh-frozen plasmas, and platelet concentrates trans-
fused during the observation period, and assessed the 
amount of blood products (such as fibrinogen and pro-
thrombin complex concentrates) that were administered.
The primary efficacy endpoint was any thromboem-
bolic event associated with the extracorporeal lung assist 
device, such as clotting of the oxygenator, the pump or of 
the ECMO/pECLA cannulas with or without necessary 
replacement. Also recorded was the number of extracor-
poreal circuit systems replaced during the observation 
period due to clotting. Secondary efficacy endpoints were 
new thromboembolic complications (defined as deep 
venous thrombosis identified by duplex Doppler), pulmo-
nary embolism (diagnosed by computed tomography), 
limb ischemia, or occlusive stroke found clinically or by 
imaging techniques.
For evaluation of the controllability and efficiency arga-
troban and heparin, all targeted activated partial throm-
boplastin time values (aPTT) were analyzed in the first 
consecutive 14  days of therapy. We assessed the con-
trollability of aPTT values within the therapeutic range 
of 50–75 s, and recorded repeated aPTT measurements 
per day that were necessary to achieve and control for the 
targeted aPTT corridor.
Statistical analyses
Discrete variables are given as counts or percentage, 
and continuous variables as medians with interquartile 
ranges. For demographics and patient characteristics, 
differences between the groups were assessed using (ret-
rospective) Fisher’s exact test for categorical variables or 
Mann–Whitney U test for continuous variables when 
appropriate. Friedman test and multivariate nonpara-
metric analysis for longitudinal data (MANOVA; Brun-
ner’s analysis) were applied for analysis of data over time. 
Event rates are presented as the mean (±standard devia-
tion) of the (individual) number of events divided by 
the (individual) time under exposure (days) on ECMO/
pECLA multiplied by 100 and were analyzed with the 
Mann–Whitney U test. They reflect the average number 
of events per 100 patient-days on ECLS in the respective 
groups. Statistical analyses were performed with IBM 
SPSS Statistics version 20 (SPSS, Chicago, IL, USA) and 
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). Dif-
ferences were considered significant at p < 0.05. All tests 
should be understood as constituting exploratory data 




A total of 535 critically ill patients admitted for ARDS 
were treated between January 2007 and December 2014. 
Of these, 319 patients (59.6%) underwent extracorporeal 
lung assist with either ECMO or pECLA. Of this latter 
group, 43 patients (12.2%) received argatroban for more 
than 2 days; 4 of these patients dropped out due to miss-
ing data or missing matches leaving 39 patients for the 
analyses. Eventually, we identified 39 matched control 
patients yielding a total study population of 78 patients 
(Fig. 1). Characteristics of the study population at base-
line are presented in Table 1.
There were no significant differences between the 
two study groups for age, sex and BMI, or for sever-
ity of illness and organ failure scores at ICU admission. 
Also, applying the three categories of the Berlin defini-
tion of ARDS and the lung injury score showed there 
were no significant differences with respect to severity 
of lung failure. Parameters of pulmonary gas exchange 
and mechanical ventilation were similar in both groups. 
Pneumonia was the most common cause of lung fail-
ure. The predominant extracorporeal lung assist proce-
dure was ECMO (55%). Although there was a trend for 
patients with heparin to be longer on extracorporeal lung 
support, this did not reach significance.
Observation period and reason for argatroban
The observation period (i.e., time on extracorporeal lung 
support with an anticoagulant) was 10 (5; 20) days in the 
argatroban group and 11 (8; 25) days in the heparin group 
(p =  0.32). Argatroban was started in 13 patients (33%) 
due to suspected HIT, presenting with typical thrombo-
cytopenia and positive laboratory testing for anti-PF4 
antibodies. In total, 26 patients (66%) were non-respon-
sive to heparin, or HIT was suspected but not confirmed. 
Argatroban was started at a median of 64 (36; 205) h after 
initiation of extracorporeal lung support.
Bleeding and thrombotic complications
As primary safety outcome measures, significant major/
minor bleeding episodes and thrombotic complications 
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were assessed (Table 2). Overall, major bleeding occurred 
relatively seldom, with a small number of critical events in 
both groups. Only 1 patient in the argatroban group and 
3 patients in the heparin group developed severe intrac-
ranial bleeding while on ECMO or pECLA (p = 0.60). In 
both groups, minor bleedings (e.g., epistaxis or gingival 
bleeding) occurred significantly more often than major 
bleedings (47 vs. 217 events in total; p < 0.05). However, 
there were no significant differences in major or minor 
bleedings between the groups with respect to the num-
ber of affected patients or the respective event rates. The 
incidence of new thromboembolic events (e.g., deep vein 
thrombosis or pulmonary embolism) was generally low 
and did not differ between the groups.
Extracorporeal lung support device‑associated 
complications
Thromboembolic events associated with the extracorpor-
eal lung assist device (e.g., clotting) occurred infrequently 
(Table 2). There was no significant difference between the 
groups with respect to clotting of the inflow/outflow can-
nulas and with respect to the number of affected patients. 
Although the number of extracorporeal circuit systems 
replaced during the observation period due to clotting 
varied widely, there was no significant difference between 
the two groups. By trend, replacements of the pECLA 
oxygenator occurred more frequently in the argatroban 
group.
Transfusions, blood products and coagulation factors
There was no significant difference between the groups 
for units of packed red blood cells, fresh-frozen plasmas 
and platelet concentrates that were transfused during 
the observation period on extracorporeal lung support 
(Table 3). Also, there was no difference in the amount of 
blood products and coagulation factors that were admin-
istered to the two groups. Antithrombin III was signifi-
cantly more often applied in the heparin group.
Dosing, efficiency and controllability
The mean starting dose of argatroban was 0.3 (±0.04) 
µg/kg/min, and the average maintenance dose was 0.26 
(±0.038) µg/kg/min. The administered mean dose had to 
be stepwise decreased in the first three days to maintain 
an aPTT level below the upper limit of 75 s; (Fig. 2a; left 
panel). All mean aPTT values were sufficiently within the 
Fig. 1 Study population and recruitment of the matched controls
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Table 2 Bleeding, thrombotic complications and replacements of extracorporeal lung support devices of ARDS patients 
on ECMO/pECLA with either argatroban or heparin
Discrete variables are presented as absolute numbers of affected patients and absolute numbers of events during the observation period (i.e., the time (days) on 
ECLS receiving either argatroban or heparin as anticoagulant). Contingency analyses were performed using Fisher’s exact test of retrospective data (no statistically 
significant differences between the argatroban and heparin group.) Event rates are presented as the mean (±standard deviation) of the (individual) number of events 
divided by the (individual) time under exposure (days) on ECMO/pECLA multiplied by 100 and were analyzed with the Mann–Whitney U test. They reflect the average 
number of events per 100 patient-days on ECLS in the respective groups
* p < 0.05. Extracorporeal lung support: pECLA pumpless extracorporeal lung assist or ECMO extracorporeal membrane oxygenation; complete data were available for 
all 78 patients
Argatroban Heparin p values
Patients (n) Events. (n) Event rate (mean) Patients (n) Events. (n) Event rate (mean) p (event rates)
Major bleedings: all 11 14 2.7 (±5.3) 13 33 3.8 (±6.8) 0.57
Intracranial 1 1 0.07 (±0.4) 3 3 0.7 (±2.6) 0.24
Pulmonary 6 8 1.5 (±4.1) 8 17 1.2 (±2.8) 0.73
Gastrointestinal 3 3 0.47 (±1.71) 5 8 1.4 (±4.1) 0.32
Other 2 2 0.66 (±3.2) 1 5 0.4 (±1.2) 0.67
Minor bleedings: all 30 91 19.3 (±19.4) 31 126 22.1 (±23.7) 0.58
Catheters. Gingival. Skin 29 84 18.1 (±19.6) 30 116 19.3 (±18.6) 0.62
Wounds 2 2 5.0 (±2.4) 9 10 2.8 (±8.2) 0.06
Other 1 5 2.8 (17.3) 0 0 0 (±0) 1.00
Thrombotic complications: all 6 11 2.5 (±9.9) 3 4 0.8 (±2.5) 0.54
Deep vein thrombosis 1 1 0.38 (±2.3) 0 0 0 (±0) 1.00
Pulmonary embolism 1 2 0.7 (±4.7) 1 1 0.09 (±0.57) 1.00
Cerebrovascular event 1 1 0.3 (±1.6) 1 1 0.2 (±1.3) 1.00
Mesenteric infarction 0 0 0 (±0) 0 0 0 (±0) –
Myocardial infarction 0 0 0 (±0) 0 0 0 (±0) –
Peripheral artery closure 1 1 0.4 (±2.3) 0 0 0 (±0) 1.00
Other 4 6 0.8 (±3.3) 2 2 0.5 (±2.2) 0.61
Replacements
pECLA cannula 0 0 0 0 0 0 –
pECLA oxygenator 8 29 12.9 (±10.1) 10 23 5.4 (±7.5) 0.17
ECMO cannula 7 9 1.4 (±3.7) 4 6 2.1 (±7.8) 0.72
ECMO oxygenator 15 36 8.5 (±14) 11 21 5.5 (±7) 0.88
Table 3 Transfusions and blood products and of ARDS patients on ECMO/pECLA with either argatroban or heparin
Discrete variables are presented as absolute numbers per patient-day on extracorporeal lung support and were analyzed with Fisher’s exact test for nonparametric 
samples
* p < 0.05; g: gram; IU international units; complete data were available for all 78 patients
Argatroban (n = 39) Heparin (n = 39) p values
n per patient‑day  
on extracorporeal lung support
n per patient‑day  
on extracorporeal lung support
Transfusions
 Packed red blood cells 0.98 1.2 0.61
 Fresh‑frozen plasma 1.8 1.77 0.86
 Platelet concentrate 0.28 0.49 0.21
Blood products and coagulation factors
 Fibrinogen (g) 0.05 0.01 0.60
 Prothrombin complex concentrate (IU) 1.96 3.53 0.75
 Antithrombin III (IU) 9.7 117 <0.01*
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targeted aPTT corridor (Fig.  2b; left panel). Mean start-
ing dose of heparin was 498 (±336) IU/h, and the average 
dose was 823 (±124) IU/h. The mean dose of heparin had 
to be stepwise increased in the first four days to achieve 
or maintain an appropriate aPTT level; this effect was sig-
nificant from day 2 onwards (Fig. 2a; right panel). Signifi-
cantly more aPTT values were below the targeted corridor 
in the heparin group (heparin 66.5 vs. 33.5% argatroban; 
p  < 0.001). Also, mean aPTT values were steadily below 
the intended 50  s in the first four days of observation 
(Fig. 2b; right panel). In order to control for aPTT values 
and to adjust the anticoagulant dose, repetitive measure-
ments of the aPTT were significantly more often made 
in the argatroban group in the first two days (p  <  0.05). 
Repeated aPTT measurements per day decreased sig-
nificantly over time in both groups; however, this effect 
was more pronounced in the argatroban group (arga-
troban p < 0.0001; heparin p < 0.01). Analyzing the aPTT 
exceedances over time revealed a significant decrease in 
the argatroban group, but not in the heparin group (arga-
troban p < 0.0001; heparin 0.26) (Fig. 3a). Also, the num-







































































Fig. 2 Comparisons of a dosage; b aPPT values; in ARDS patients undergoing extracorporeal lung support with either argatroban or heparin as 
anticoagulant in the first consecutive 14 days of therapy left: argatroban; right: heparin. Data are presented as mean ± standard error of the mean 
(SEM) and were analyzed with a Mann–Whitney U test for nonparametric samples. *p < 0.05; **p < 0.01 compared to day 1. APTT activated thrombo‑
plastin time; µg/kg/min microgram per kilogram bodyweight per minute; IU/h international units per hour; s seconds; extracorporeal lung support: 
pECLA pumpless extracorporeal lung assist or ECMO extracorporeal membrane oxygenation
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significant decrease in both groups over time (argatroban 
and heparin, p < 0.0001) (Fig. 3b).
Correlation between aPTT and bleeding episodes or 
thrombotic events
The incidence of bleeding did not correlate with the number 
of aPTT values exceeding 75 s in both groups (argatroban 
r = −0.04, p = 0.99; heparin r = 0.13, p = 0.55). Also, there 
was no significant correlation between bleeding and the 
maximum aPTT value (argatroban r  =  −0.10, p  =  0.54; 
heparin r = 0.03, p = 0.84) (Fig. 4b). In both groups, patients 
with and without bleeding complications showed no signifi-
cant difference in their mean aPTT values; also, there was 
no difference between the argatroban and heparin groups 
(Fig. 4d). Thrombotic events did not correlate with the num-
ber of aPTT values below 50 s or with the minimum aPTT 
value (argatroban r = −0.05, p = 0.89; heparin r = 0.136, 
p  =  0.89) (Fig.  4a). Also, mean aPTT values showed no 
significant difference in patients with and without throm-
botic events in both treatment groups (Fig. 4c).
Discussion
This study focused on the efficacy, safety and controlla-
bility of argatroban in patients with ARDS and extracor-
poreal lung assist devices (ECMO or pECLA). Overall, 
both anticoagulants enabled therapeutic aPTT values 
in critically ill patients and were suitable to operate the 
extracorporeal lung assist device sufficiently and safely, 
even for a longer period of time. No differences were 
found between the two groups with respect to bleeding, 
thrombosis or transfusion. The controllability of both 
anticoagulants significantly improved over the course of 
time, with an increasing probability to reach the targeted 
aPTT corridor.
The present study included patients treated for ARDS 
in a single center. Matching for standard parameters 
and severity of illness identified an appropriate control 
group. ARDS patients in this study were characterized 
by relatively severe medical conditions, as reflected by 
high median APACHE II and SAPS II scores at hospital 
admission. On average, severity scores were higher than 
in comparable recent studies [13] and even higher than 
in the ALIVE study [14]. Also, parameters of pulmonary 
gas exchange and invasiveness of mechanical ventila-
tion indicated severe lung failure. This might be due to 
our study population, which consisted of very severely 
affected patients admitted to our ARDS center specifi-
cally because their medical condition is poor. On average, 
more than two-thirds of our patients are transferred from 
other hospitals [15].
Argatroban was started in 13 patients due to a clini-
cal diagnosis of HIT, presenting with typical thrombo-
cytopenia and positive laboratory testing for anti-pF4 
antibodies. This represents about 4% of ARDS patients 
undergoing extracorporeal lung support, a percentage 
similar to that reported by others [16]. It is estimated 
that up to 5% of patients who receive heparin are at risk 
to develop HIT [4]. However, in the present study, the 
majority of patients who received argatroban were either 
non-responsive to heparin or HIT was suspected but not 
confirmed by laboratory testing. There are many reasons 
why ARDS patients on extracorporeal lung support may 
develop a decrease in platelet count; for example, throm-
bocytopenia might arise due to sepsis, platelet activation 
or a certain consumption by the extracorporeal circuit. 
However, the differential diagnosis of HIT in critically 
ill patients remains a challenge [17] and was not in the 
scope of our study. Association of a positive 4T score, 
anti-PF4 and aggregability tests is mandatory to con-
firm HIT. The threshold to change anticoagulation from 
standard heparin to argatroban on our ICU is relatively 
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relative effects:  aPTT values >75 seconds 
relative effects: aPTT values <50 seconds 
Fig. 3 a Exceedances of aPTT values >75 s over the course of time in 
ARDS patients undergoing extracorporeal lung support with either 
argatroban or heparin as anticoagulant; depicted as relative effect 
over time; argatroban ****p < 0.0001; heparin p = 0.26. b aPTT values 
below 50 s over the course of time, depicted as relative effect over 
time; argatroban and heparin ****p < 0.0001. The relative effect does 
not represent the measured values of that parameter, but presents 
(on a scale of 0–1) the treatment effect of the specific group, relative 
to all groups and therefore to a ‘mean’ treatment effect. Multivariate 
nonparametric analysis for longitudinal data (MANOVA; Brunner’s 
analysis)
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low. Further, patients who were once switched to arga-
troban upon suspected HIT with ultimately negative 
HIT testing were not necessarily switched back to hepa-
rin. This might explain the relatively high rate of patients 
receiving argatroban in our study population.
For patients with HIT, the approved initial dose of arga-
troban is 2 µg/kg/min. Our study population, comprising 
critically ill ARDS patients with concomitant organ fail-
ure, required substantially lower doses of (approximately) 
0.26  µg/kg/min argatroban to achieve the therapeutic 
aPTT goal. This effect might be even more pronounced 
when the number of failing organ systems increases [18]. 
Our data are consistent with these findings and also sup-
port other studies, which also recommended much lower 
argatroban doses in critically ill patients [13, 19–21]. 
There are no specific guidelines for dosing in ARDS 
patients on extracorporeal gas exchange. In our center, 
the established starting dose is 0.3 µg/kg/min. The base-
line aPTT value, the evaluation of hepatic impairment 
and the presence of multi-organ-system failure should be 
taken into account when starting argatroban.
Although major and minor bleeding complications 
were similar in both groups, there were significantly 
fewer major bleedings than minor bleedings in both 
groups. The rates seen in our study are similar to those 
reported by others [16]. Major bleedings (e.g., pulmonary 
or intracranial bleedings) were relatively rare events; we 
found four cases of severe intracranial bleeding, which 
corresponds to 5% of all our assessed patients. The ELSO 
reports rates of major intracranial hemorrhage of up to 
4% [22]; in most of these cases, the outcome is deleteri-
ous. The slightly higher rate found in our study might 






























































































Fig. 4 a Correlation of any thromboembolic event (n) and the minimal aPTT value (s) and b correlation of any bleeding event (n) and the maximal 
aPTT value (s) in ARDS patients undergoing extracorporeal lung support with either argatroban or heparin as anticoagulant (solid circle = arga‑
troban; open square = heparin). Data are presented as scattered plot; each dot represents a patient with anticoagulation and the associated number 
of thromboembolic episodes or bleeding events, respectively. Vertical dotted lines represent the targeted aPTT corridor of 50–75 s. c, d Comparison 
of mean aPTT values of ARDS patients undergoing extracorporeal lung support with either argatroban or heparin as anticoagulant with or without 
thromboembolic events (c) and with or without any bleeding episode (d). Data are presented as mean ± standard error of the mean (SEM) and 
were analyzed with a Mann–Whitney U test for nonparametric samples. n.s. no significant differences between argatroban and heparin group; n 
number; APTT activated thromboplastin time; s seconds
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be explained by the more severe medical condition of 
our patients, as evidenced by high APACHE and SAPS 
II scores. Also, impairment of the coagulation system 
due to sepsis or secondary organ failure, and additional 
anticoagulation, might render ARDS patients prone to 
intracranial hemorrhage. However, in this respect, we 
found no significant differences between argatroban and 
heparin.
Thromboembolic events are potentially harmful or 
even life-threatening events in patients with ARDS. 
Although such events are a major complication of extra-
corporeal lung support therapy, data on the clinical 
significance are sparse [23]. As compared to bleeding epi-
sodes, thromboembolism rarely occurred in the present 
study; also, there was no fatality due to thrombotic failure 
of the extracorporeal lung support device. In the study 
of Weingart et al., about 25% of patients on extracorpor-
eal lung support needed at least one replacement of the 
membrane oxygenator [24]. In our study, about 40% of 
patients needed such replacements. By trend, replace-
ments of the pECLA oxygenator occurred more often in 
the argatroban group than in the heparin group. We did 
not observe this with regard to the ECMO oxygenator. 
However, the overall number of affected patients did not 
differ significantly between the two groups. Blood flow is 
much lower in pECLA than in ECMO; also, there may be 
areas with relative stasis, which can lead to thrombus for-
mation. Nevertheless, the desired ranges of aPTT values 
in patients with a running system of either kind are com-
parable for pECLA and ECMO. Therefore, we decided to 
include both devices in our study.
Interestingly, we found no significant correlation 
between aPTT values and bleeding or thromboembolic 
events. Patients with aPTT values exceeding the desired 
therapeutic range did not necessarily develop bleeding 
complications. Vice versa, patients with aPTT values 
below the targeted therapeutic range did not necessar-
ily develop thromboembolic events. However, practically 
all the thromboembolic events occurred when minimal 
aPTT values were below 50 s. This is in line with Trudz-
inski et  al., who found an aPTT level below 50  s to be 
predictive for thromboembolism in ARDS patients under 
ECMO [25]. On the other hand, almost all bleeding 
events occurred when the maximal aPTT of the patients 
was above 50–60  s. Strikingly, more than two-thirds of 
all bleeding events were associated with maximum aPTT 
values above 75 s. Although these results only reflect the 
population of this study, we propose that this aPTT value 
could be regarded as the utmost tolerable upper limit 
under extracorporeal lung support to avoid hemorrhage. 
However, management of anticoagulation in ARDS 
patients with extracorporeal lung support is not clearly 
defined. On the basis of our findings, we suggest aPTT 
levels around 50  s, which is in accordance with most 
other recommendations and ELSO guidelines suggest-
ing a range 1.5–2.5 times baseline value [19, 21, 24–26]. 
Development of bleeding might be multifactorial in the 
intensive care setting and not only dependent on anti-
coagulation. In particular, impairment of liver function 
might be held responsible for dysfunction of the coagu-
lation system [27]. Also, volume overload or right-sided 
heart failure is a typical complication in ARDS patients, 
which might ultimately lead to hepatic congestion. Over-
all, in the present study there was no difference between 
argatroban and heparin with respect to bleeding. Also, 
there were no significant differences in blood transfu-
sions (a surrogate for blood loss). Our results for ARDS 
patients on ECMO or pECLA are similar to data from a 
recent retrospective study based on a prospective cohort 
database which found an average of one red blood cell 
per patient-day on VV-ECMO [28]. Thus, argatroban 
appears to be a safe and suitable anticoagulant in criti-
cally ill ARDS patients on extracorporeal lung support.
Finally, we evaluated the controllability of argatroban. 
Firstly, it enabled therapeutic aPTT values to adequately 
perform extracorporeal lung support, even for a long 
time. However, repetitive measurements of the aPTT to 
adjust for the aPTT goal were significantly more often 
necessary in the argatroban group in the first four days 
of therapy. Only a few comparable studies are available 
on this topic. For example, Treichl et  al. [29] report up 
to three necessary dose adjustments in every patient in 
order to achieve a distinct aPTT goal. Most other studies 
do not report details on dose adjustments or aPTT moni-
toring. Nevertheless, in our study, the controllability of 
argatroban significantly improved over the first few days, 
with an increasing probability to reach the targeted aPTT 
corridor. The mechanism of ‘PTT confounding’ might 
have been an interfering factor. This condition is defined 
as a situation where patient-related clinical factors may 
result in changes in aPTT values that are misleading with 
respect to indicating the true level of anticoagulation 
[30]. As a consequence, dosing of argatroban might have 
been insufficient in some cases.
The present study has some limitations. First, it is ret-
rospective and, although it is one of the largest studies 
on this topic, the sample size is relatively small. Thus, 
the study may be underpowered to detect significant 
differences in mortality, bleeding outcomes or trans-
fusion. Therefore, generalization of these results to 
other patients undergoing extracorporeal lung sup-
port requires considerable caution. Also, in this study 
the indication for extracorporeal lung support was 
lung failure. Extracorporeal lung support was primarily 
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cannulated veno-venously, and the results may not allow 
conclusions to be drawn in the case of a veno-arterial 
scenario. The patients of this study had very high sever-
ity scores. Therefore, there might be different results or 
thresholds in other patient populations. Another major 
limitation is that bleeding episodes and thromboembolic 
events were manually extracted from the patients’ files, 
which can result in underestimation of the overall inci-
dence. There may be residual confounding that is not 
captured, such as confounding by indication or indica-
tor. Finally, an additional limitation of the present study 
is the absence of other parameters of anticoagulation 
used.
Conclusion
Argatroban appears to be a feasible, effective and safe 
anticoagulant for critically ill ARDS patients undergoing 
extracorporeal lung support. A moderate systemic anti-
coagulation with aPTT values around 50  s seems to be 
sufficient to safely operate the lung assist device.
List of abbreviations
ARDS: Acute respiratory distress syndrome; aPTT: Activated partial thrombo‑
plastin time; MANOVA: Multivariate nonparametric analyses of longitudinal 
data; VV‑ECMO: Veno‑venous extracorporeal membrane oxygenation; HIT: 
Heparin‑induced thrombocytopenia; pECLA: Pumpless extracorporeal lung 
assist; ICU: Intensive care unit; BMI: Body mass index; SAPS: Simplified Acute 
Physiology Score; APACHE: Acute Physiology And Chronic Health Evaluation; 
SOFA: Sequential Organ Failure Assessment; TISS‑28: Therapeutic Intervention 
Scoring System‑28; PIP: Positive inspiratory pressure; PEEP: Positive end‑expira‑
tory pressure; FiO2: Fraction of inspired oxygen.
Authors’ contributions
MM, PB and SW contributed to the conception and design of the study, data 
collection, data analysis and interpretation and drafted the manuscript. BW, 
DS, MG, AG and CP contributed to data interpretation and revised the manu‑
script critically for important intellectual content. MM and SW are guarantors 
of the paper taking responsibility for the integrity of the work as a whole, 
from conception to published article. All authors read and approved the final 
manuscript.
Acknowledgements
The authors thank Prof. K.D. Wernecke for supporting statistical data analysis 
and Laraine Visser‑Isles for English language editing.
Competing interests
This study was partly supported by a grant from Mitsubishi Tanabe Pharma 
GmbH.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article and its supplementary information files.
Ethics approval and consent to participate
After written consent from the data protection officer, this study was 
approved by the Charité ethics commission (EA1/223/12). This study had all 
necessary consent to participate from all patients involved.
Funding
This study was partly supported by a grant from Mitsubishi Tanabe Pharma 
GmbH. The funding body had no influence on the design of the study and 
collection, analysis, and interpretation of data and writing of the manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 15 March 2017   Accepted: 20 July 2017
References
 1. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin‑
induced thrombocytopenia with thrombosis: incidence, analysis of risk 
factors, and clinical outcomes in 108 consecutive patients treated at a 
single institution. Am J Hematol. 1997;56(1):12–6.
 2. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is 
not required for detection of antibodies associated with heparin‑induced 
thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22–31.
 3. Greinacher A, Ittermann T, Bagemühl J, Althaus K, Fürll B, Selleng S, et al. 
Heparin‑induced thrombocytopenia: Towards standardization of platelet 
factor 4/heparin antigen tests. J Thromb Haemost. 2010;8(9):2025–31.
 4. Martel N, Lee J, Wells PS. Risk for heparin‑induced thrombocytopenia 
with unfractionated and low‑molecular‑weight heparin thromboprophy‑
laxis: a meta‑analysis. Blood. 2005;106(8):2710–5.
 5. Linkins L‑A, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, 
Crowther M. Treatment and prevention of heparin‑induced thrombocy‑
topenia: antithrombotic therapy and prevention of thrombosis: American 
College of Chest Physicians evidence‑based clinical practice guidelines. 
Chest J. 2012;141(2 suppl):e495S–530S.
 6. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, 
et al. Argatroban anticoagulant therapy in patients with heparin‑induced 
thrombocytopenia. Circulation. 2001;103(14):1838–43.
 7. Zangrillo A, Landoni G, Biondi‑Zoccai G, Greco M, Greco T, Frati G, et al. 
A meta‑analysis of complications and mortality of extracorporeal mem‑
brane oxygenation. Crit Care Resusc. 2013;15(3):172.
 8. Karagiannidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, et al. 
Extracorporeal membrane oxygenation: evolving epidemiology and mor‑
tality. Intensive Care Med. 2016;42(5):889–96.
 9. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, 
Annich GM. Association of hospital‑level volume of extracorporeal 
membrane oxygenation cases and mortality. Analysis of the extracor‑
poreal life support organization registry. Am J Respir Crit Care Med. 
2015;191(8):894–901.
 10. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan 
E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 
2012;307(23):2526–33.
 11. Deja M, Hommel M, Weber‑Carstens S, Moss M, von Dossow V, Sander 
M, Pille C, Spies C. Evidence‑based therapy of severe acute respira‑
tory distress syndrome: an algorithm‑guided approach. J Int Med Res. 
2008;36(2):211–21.
 12. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the 
adult respiratory distress syndrome. Am Rev Resp Dis. 1988;138(3):720–3.
 13. Kim SC, Tran N, Schewe JC, Boehm O, Wittmann M, Graeff I, et al. Safety 
and economic considerations of argatroban use in critically ill patients: a 
retrospective analysis. J Cardiothorac Surg. 2015;10:19.
 14. Brun‑Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski 
K, et al. Epidemiology and outcome of acute lung injury in european 
intensive care units. Results from the ALIVE study. Intensive Care Med. 
2004;30(1):51–61.
 15. Balzer F, Menk M, Ziegler J, Pille C, Wernecke KD, Spies C, et al. Predictors 
of survival in critically ill patients with acute respiratory distress syndrome 
(ARDS): an observational study. BMC Anesthesiol. 2016;16(1):108.
 16. Vo QA, Lin JK, Tong LM. Efficacy and safety of argatroban and bivalirudin 
in patients with suspected heparin‑induced thrombocytopenia. Ann 
Pharmacother. 2015;49(2):178–84.
 17. Thiele T, Selleng K, Selleng S, Greinacher A, Bakchoul T. Thrombocyto‑
penia in the intensive care unit‑diagnostic approach and management. 
Semin Hematol. 2013;50(3):239–50.
 18. Begelman SM, Baghdasarian SB, Singh IM, Militello MA, Hursting MJ, 
Bartholomew JR. Argatroban anticoagulation in intensive care patients: 
Page 12 of 12Menk et al. Ann. Intensive Care  (2017) 7:82 
effects of heart failure and multiple organ system failure. J Intensive Care 
Med. 2008;23(5):313–20.
 19. Beiderlinden M, Treschan T, Görlinger K, Peters J. Argatroban in extracor‑
poreal membrane oxygenation. Artif Organs. 2007;31(6):461–5.
 20. Yoon JH, Yeh RW, Nam KH, Hoffman WD, Agnihotri AK, Jang IK. Safety and 
efficacy of the argatroban therapy during the early post‑cardiac surgery 
period. J Thromb Thrombolysis. 2010;30(3):276–80.
 21. Saugel B, Phillip V, Moessmer G, Schmid RM, Huber W. Argatroban 
therapy for heparin‑induced thrombocytopenia in ICU patients with 
multiple organ dysfunction syndrome: a retrospective study. Crit Care. 
2010;14(3):R90.
 22. Thiagarajan RR, Barbaro RP, Rycus PT, Mcmullan DM, Conrad SA, Forten‑
berry JD, et al. Extracorporeal life support organization registry interna‑
tional report 2016. ASAIO J. 2017;63(1):60–7.
 23. Sklar MC, Sym E, Lequier L, Fan E, Kanji HD. Anticoagulation practices dur‑
ing venovenous extracorporeal membrane oxygenation for respiratory 
failure. A systematic review. Ann Am Thorac Soc. 2016;13(12):2242–50.
 24. Weingart C, Lubnow M, Philipp A, Bein T, Camboni D, Müller T. Compari‑
son of coagulation parameters, anticoagulation, and need for transfusion 
in patients on interventional lung assist or veno‑venous extracorporeal 
membrane oxygenation. Artif Organs. 2015;39(9):765–73.
 25. Trudzinski FC, Minko P, Rapp D, Fähndrich S, Haake H, Haab M, et al. 
Runtime and aPTT predict venous thrombosis and thromboembolism 
in patients on extracorporeal membrane oxygenation: a retrospective 
analysis. Ann Intensive Care. 2016;6(1):66.
 26. Richard C, Argaud L, Blet A, Boulain T, Contentin L, Dechartres A, et al. 
Extracorporeal life support for patients with acute respiratory distress 
syndrome: report of a consensus conference. Ann Intensive Care. 
2014;4(1):15.
 27. Doepker B, Mount KL, Ryder LJ, Gerlach AT, Murphy CV, Philips GS. Bleed‑
ing risk factors associated with argatroban therapy in the critically ill. J 
Thromb Thrombolysis. 2012;34(4):491–8.
 28. Aubron C, Cheng AC, Pilcher D, Leong T, Magrin G, Cooper DJ, et al. Fac‑
tors associated with outcomes of patients on extracorporeal membrane 
oxygenation support: a 5‑year cohort study. Crit Care. 2013;17(2):R73.
 29. Treichl B, Bachler M, Lorenz I, Friesenecker B, Oswald E, Schlimp CJ, et al. 
Efficacy of argatroban in critically ill patients with heparin resistance: a 
retrospective analysis. Semin Thromb Hemost. 2015;41(1):61–7.
 30. Warkentin TE. Anticoagulation failure in coagulopathic patients: PTT 
confounding and other pitfalls. Expert Opin Drug Saf. 2014;13(1):25–43.
